Inivata to present results of analytical validation at the AACR Annual Meeting 2016

Inivata, a global clinical cancer genomics company, will present performance data from the analytical validation of its enhanced TAm-SeqTM (eTAm-SeqTM) proprietary platform for broad molecular profiling, at the American Association for Cancer Research (AACR) Annual Meeting 2016 taking place April 16-20 in New Orleans.

Inivata employs the precision of circulating tumor DNA (ctDNA) analysis to improve targeted cancer care. Inivata will present data demonstrating eTAm-SeqTM molecular profiling as a robust and reproducible method exhibiting high sensitivity and specificity for the detection of genomic alterations in ctDNA. eTAm-Seq profiling of clinical samples revealed the detection of mutations at frequencies that may be missed by less sensitive assays. The analytical validation of eTAm-Seq supports its use in prospective clinical studies to demonstrate the clinical validation and utility in using ctDNA analysis for precision medicine applications particularly for patients where tumor tissue is limited or unavailable.

Details of the poster presentation are as follows:

Poster Session: Genomic Technologies and Analyses

Title: Analytical performance and validation of an enhanced TAm-Seq circulating tumor DNA sequencing assay

Date and Time: Tuesday, April 19, 1:00 – 5:00 PM

Abstract Number: 3639

Location: Section 7

Poster Board Number: 9

Presenter: Davina Gale, co-founder and Head of Molecular Diagnostics, Inivata

Co-authors include scientists and clinicians from Inivata Ltd. and Institut Gustave Roussy.

The poster will be uploaded to the Conference Presentation section of Inivata’s corporate website upon completion of the session to abide by the conference’s embargo policy.

Nitzan Rosenfeld, Inivata CSO, said: “Inivata is pleased to present the results of analytical validation of our enhanced TAm-Seq assay. I am immensely proud of our team, and delighted that we have achieved this excellent performance for our assay, placing Inivata at the front line of sensitivity for liquid biopsies. Having completed our validation to strict quality standards means that our assay is now fit for clinical use. Our ongoing collaborations have shown promising results so far, demonstrating how our test could impact targeted cancer care. Studies we are now undertaking will help establish the clinical utility of this approach and the benefit of Inivata’s liquid biopsies.”